VYGR Oct 2024 10.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 02:06PM EDT
| Previous Close | 3.0000 |
| Open | 3.0000 |
| Bid | 0.0000 |
| Ask | 3.6000 |
| Strike | 10.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 3.0000 - 3.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 19 |
GlobeNewswireVoyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer’s disease. The objective of the randomized, double-blind, placebo-controlled, SAD trial is to evaluate the safety and
- Thomson Reuters StreetEvents
Q1 2024 Voyager Therapeutics Inc Earnings Call
Q1 2024 Voyager Therapeutics Inc Earnings Call
- GuruFocus.com
Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Discover how Voyager Therapeutics Inc (VYGR) is advancing its neurogenetic medicine pipeline and strengthening financial stability through strategic collaborations.
© 2024 Yahoo. All rights reserved.